- Home
- MAC vs AXSM Comparison
MAC vs AXSM Comparison
Compare MAC & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAC
- AXSM
- Stock Information
- Founded
- MAC 1964
- AXSM 2012
- Country
- MAC United States
- AXSM United States
- Employees
- MAC N/A
- AXSM N/A
- Industry
- MAC Real Estate Investment Trusts
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- MAC Real Estate
- AXSM Health Care
- Exchange
- MAC Nasdaq
- AXSM Nasdaq
- Market Cap
- MAC 5.1B
- AXSM 4.8B
- IPO Year
- MAC 1994
- AXSM 2015
- Fundamental
- Price
- MAC $14.68
- AXSM $104.46
- Analyst Decision
- MAC Hold
- AXSM Strong Buy
- Analyst Count
- MAC 12
- AXSM 15
- Target Price
- MAC $18.62
- AXSM $171.00
- AVG Volume (30 Days)
- MAC 2.8M
- AXSM 912.2K
- Earning Date
- MAC 04-29-2025
- AXSM 05-05-2025
- Dividend Yield
- MAC 4.64%
- AXSM N/A
- EPS Growth
- MAC N/A
- AXSM N/A
- EPS
- MAC N/A
- AXSM N/A
- Revenue
- MAC $899,298,000.00
- AXSM $385,693,000.00
- Revenue This Year
- MAC $1.69
- AXSM $63.85
- Revenue Next Year
- MAC N/A
- AXSM $63.93
- P/E Ratio
- MAC N/A
- AXSM N/A
- Revenue Growth
- MAC 5.01
- AXSM 42.53
- 52 Week Low
- MAC $12.48
- AXSM $64.11
- 52 Week High
- MAC $22.27
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- MAC 41.01
- AXSM 41.94
- Support Level
- MAC $13.40
- AXSM $86.99
- Resistance Level
- MAC $17.94
- AXSM $103.75
- Average True Range (ATR)
- MAC 1.11
- AXSM 5.84
- MACD
- MAC -0.02
- AXSM -0.01
- Stochastic Oscillator
- MAC 40.29
- AXSM 56.74
About MAC Macerich Company (The)
The Macerich Company invests in premium mall assets. The company owns 28 regional malls in its consolidated portfolio and 14 regional malls in its unconsolidated portfolio along with three power centers and seven other real estate assets. The company's total portfolio has 45.5 million square feet of gross leasable area and averaged $836 sales per square foot over the 12 months ended in December 2023.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.